AUTHOR=Than Nandor Gabor , Romero Roberto , Tarca Adi Laurentiu , Kekesi Katalin Adrienna , Xu Yi , Xu Zhonghui , Juhasz Kata , Bhatti Gaurav , Leavitt Ron Joshua , Gelencser Zsolt , Palhalmi Janos , Chung Tzu Hung , Gyorffy Balazs Andras , Orosz Laszlo , Demeter Amanda , Szecsi Anett , Hunyadi-Gulyas Eva , Darula Zsuzsanna , Simor Attila , Eder Katalin , Szabo Szilvia , Topping Vanessa , El-Azzamy Haidy , LaJeunesse Christopher , Balogh Andrea , Szalai Gabor , Land Susan , Torok Olga , Dong Zhong , Kovalszky Ilona , Falus Andras , Meiri Hamutal , Draghici Sorin , Hassan Sonia S. , Chaiworapongsa Tinnakorn , Krispin Manuel , Knöfler Martin , Erez Offer , Burton Graham J. , Kim Chong Jai , Juhasz Gabor , Papp Zoltan TITLE=Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia JOURNAL=Frontiers in Immunology VOLUME=9 YEAR=2018 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01661 DOI=10.3389/fimmu.2018.01661 ISSN=1664-3224 ABSTRACT=

Preeclampsia is a disease of the mother, fetus, and placenta, and the gaps in our understanding of the complex interactions among their respective disease pathways preclude successful treatment and prevention. The placenta has a key role in the pathogenesis of the terminal pathway characterized by exaggerated maternal systemic inflammation, generalized endothelial damage, hypertension, and proteinuria. This sine qua non of preeclampsia may be triggered by distinct underlying mechanisms that occur at early stages of pregnancy and induce different phenotypes. To gain insights into these molecular pathways, we employed a systems biology approach and integrated different “omics,” clinical, placental, and functional data from patients with distinct phenotypes of preeclampsia. First trimester maternal blood proteomics uncovered an altered abundance of proteins of the renin-angiotensin and immune systems, complement, and coagulation cascades in patients with term or preterm preeclampsia. Moreover, first trimester maternal blood from preterm preeclamptic patients in vitro dysregulated trophoblastic gene expression. Placental transcriptomics of women with preterm preeclampsia identified distinct gene modules associated with maternal or fetal disease. Placental “virtual” liquid biopsy showed that the dysregulation of these disease gene modules originates during the first trimester. In vitro experiments on hub transcription factors of these gene modules demonstrated that DNA hypermethylation in the regulatory region of ZNF554 leads to gene down-regulation and impaired trophoblast invasion, while BCL6 and ARNT2 up-regulation sensitizes the trophoblast to ischemia, hallmarks of preterm preeclampsia. In summary, our data suggest that there are distinct maternal and placental disease pathways, and their interaction influences the clinical presentation of preeclampsia. The activation of maternal disease pathways can be detected in all phenotypes of preeclampsia earlier and upstream of placental dysfunction, not only downstream as described before, and distinct placental disease pathways are superimposed on these maternal pathways. This is a paradigm shift, which, in agreement with epidemiological studies, warrants for the central pathologic role of preexisting maternal diseases or perturbed maternal–fetal–placental immune interactions in preeclampsia. The description of these novel pathways in the “molecular phase” of preeclampsia and the identification of their hub molecules may enable timely molecular characterization of patients with distinct preeclampsia phenotypes.